Top Page
AstraZeneca
(LSE:AZN)
AstraZeneca (AZN) vs. iShares MSCI United Kingdom ETF (EWC)
AstraZeneca Business Overview & Revenue Model
AstraZeneca Earnings Call Summary
AstraZeneca Financial Statement Overview
| Breakdown | TTM | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 | Dec 2020 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 57.30B | 52.94B | 46.58B | 44.25B | 37.11B | 29.27B |
| Gross Profit | 41.60B | 39.70B | 34.45B | 28.04B | 22.60B | 21.66B |
| EBITDA | 18.84B | 14.86B | 13.20B | 8.63B | 4.59B | 8.04B |
| Net Income | 8.45B | 6.89B | 6.06B | 3.28B | 109.85M | 3.39B |
Balance Sheet | ||||||
| Total Assets | 112.42B | 104.03B | 101.12B | 96.48B | 105.36B | 66.73B |
| Cash, Cash Equivalents and Short-Term Investments | 7.11B | 5.53B | 5.86B | 6.41B | 6.40B | 7.99B |
| Total Debt | 32.84B | 30.11B | 28.62B | 29.23B | 30.78B | 20.38B |
| Total Liabilities | 67.61B | 63.16B | 61.95B | 59.42B | 66.08B | 51.09B |
| Stockholders Equity | 44.72B | 40.79B | 39.14B | 37.04B | 39.27B | 15.62B |
Cash Flow | ||||||
| Free Cash Flow | 8.72B | 7.28B | 6.57B | 7.24B | 3.76B | 2.19B |
| Operating Cash Flow | 13.39B | 11.86B | 10.35B | 9.81B | 5.96B | 4.80B |
| Investing Cash Flow | -6.06B | -7.98B | -4.06B | -2.96B | -11.06B | -285.00M |
| Financing Cash Flow | -6.99B | -4.00B | -6.57B | -6.82B | 3.65B | -2.20B |
AstraZeneca Technical Analysis
AstraZeneca Risk Analysis
AstraZeneca Peers Comparison
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
78 Outperform | £179.70B | 27.99 | 20.09% | 1.81% | 11.89% | 25.68% | |
76 Outperform | £11.74B | 30.98 | 9.30% | 2.37% | 2.51% | 56.56% | |
75 Outperform | £57.44B | 16.97 | 23.47% | 4.12% | 0.59% | -15.36% | |
68 Neutral | £3.94B | 13.81 | 15.66% | 3.55% | 3.73% | 27.13% | |
51 Neutral | $7.46B | -0.16 | -46.00% | 2.25% | 22.82% | -2.28% | |
| ― | $51.48B | 4.94 | 13.12% | 7.05% | ― | ― | |
67 Neutral | £32.11B | 21.29 | 9.35% | 1.57% | -2.12% | 42.10% |
AstraZeneca Corporate Events
AstraZeneca PLC has announced that as of July 31, 2025, its issued share capital with voting rights consists of 1,550,682,580 ordinary shares, with no shares held in Treasury. This figure is crucial for shareholders to determine their notification requirements under the UK Financial Conduct Authority’s Disclosure and Transparency Rules, potentially impacting their interest calculations in the company.
The most recent analyst rating on (GB:AZN) stock is a Buy with a £165.00 price target. To see the full list of analyst forecasts on AstraZeneca stock, see the GB:AZN Stock Forecast page.
AstraZeneca reported strong financial results for the first half of 2025, with a significant increase in total revenue driven by growth in oncology and biopharmaceuticals. The company announced a $50 billion investment in US manufacturing and R&D, including the largest manufacturing facility in its history, to support its ambitious growth plans. This investment highlights AstraZeneca’s confidence in its innovative medicines and its commitment to achieving $80 billion in revenue by 2030. The company also reported several positive Phase III trial outcomes and regulatory approvals, reinforcing its strong position in the pharmaceutical industry.
The most recent analyst rating on (GB:AZN) stock is a Buy with a £20000.00 price target. To see the full list of analyst forecasts on AstraZeneca stock, see the GB:AZN Stock Forecast page.
AstraZeneca announced positive results from the Phase III PREVAIL trial for gefurulimab, a novel C5 inhibitor for generalized myasthenia gravis (gMG). The trial demonstrated significant improvements in daily living activities and disease severity, positioning gefurulimab as a promising self-administered treatment option, potentially enhancing patient independence and disease management.
The most recent analyst rating on (GB:AZN) stock is a Buy with a £20000.00 price target. To see the full list of analyst forecasts on AstraZeneca stock, see the GB:AZN Stock Forecast page.
AstraZeneca has announced a $50 billion investment in the United States by 2030, aimed at enhancing its medicines manufacturing and R&D capabilities. This investment, which includes the establishment of a new drug substance manufacturing center in Virginia, is expected to create tens of thousands of jobs and support AstraZeneca’s goal of reaching $80 billion in revenue by 2030, with 50% of it generated in the US. The initiative underscores AstraZeneca’s commitment to strengthening the domestic supply chain and advancing pharmaceutical manufacturing technology.
The most recent analyst rating on (GB:AZN) stock is a Buy with a £20000.00 price target. To see the full list of analyst forecasts on AstraZeneca stock, see the GB:AZN Stock Forecast page.
AstraZeneca’s CARES Phase III clinical program for anselamimab in light chain amyloidosis did not achieve statistical significance for the primary endpoint in the overall patient population. However, anselamimab showed clinically meaningful improvements in survival and cardiovascular hospitalization in a prespecified subgroup of patients, indicating potential to address a critical treatment gap. The investigational drug was well tolerated, and further evaluation is ongoing to assess its efficacy and safety, with plans to share data with global health authorities.
The most recent analyst rating on (GB:AZN) stock is a Buy with a £20000.00 price target. To see the full list of analyst forecasts on AstraZeneca stock, see the GB:AZN Stock Forecast page.
AstraZeneca announced positive results from its BaxHTN Phase III trial, where its drug Baxdrostat significantly reduced systolic blood pressure in patients with uncontrolled or treatment-resistant hypertension. This breakthrough offers a potential new treatment approach targeting aldosterone dysregulation, addressing a critical unmet need in hypertension management and potentially enhancing AstraZeneca’s position in the cardiovascular market.
The most recent analyst rating on (GB:AZN) stock is a Buy with a £20000.00 price target. To see the full list of analyst forecasts on AstraZeneca stock, see the GB:AZN Stock Forecast page.
AstraZeneca’s Imfinzi has been approved by the European Union as the first perioperative immunotherapy for muscle-invasive bladder cancer, based on the NIAGARA Phase III trial results. This approval is expected to transform the standard of care in Europe, offering a significant reduction in disease recurrence and extending survival rates, thereby setting a new benchmark for treatment in this area.
The most recent analyst rating on (GB:AZN) stock is a Buy with a £20000.00 price target. To see the full list of analyst forecasts on AstraZeneca stock, see the GB:AZN Stock Forecast page.
AstraZeneca PLC has announced that as of 30 June 2025, its issued share capital with voting rights totals 1,550,670,668 ordinary shares, with no shares held in Treasury. This figure is crucial for shareholders to calculate their interests in compliance with the UK Financial Conduct Authority’s Disclosure and Transparency Rules, impacting how stakeholders manage their shareholdings.
The most recent analyst rating on (GB:AZN) stock is a Buy with a £20000.00 price target. To see the full list of analyst forecasts on AstraZeneca stock, see the GB:AZN Stock Forecast page.
AstraZeneca, in collaboration with Daiichi Sankyo, has announced the accelerated approval of Datroway (datopotamab deruxtecan) in the US for the treatment of advanced EGFR-mutated non-small cell lung cancer (NSCLC) in patients who have previously undergone EGFR-directed therapy and platinum-based chemotherapy. This approval marks the first TROP2-directed therapy for lung cancer in the US, offering a new treatment option for patients with limited alternatives. The approval is based on promising results from the TROPION-Lung05 and TROPION-Lung01 trials, demonstrating a significant objective response rate and duration of response. The introduction of Datroway is expected to strengthen AstraZeneca’s position in the oncology market, providing a novel option for patients with advanced disease and potentially expanding its use in other cancer types.
The most recent analyst rating on (GB:AZN) stock is a Buy with a £20000.00 price target. To see the full list of analyst forecasts on AstraZeneca stock, see the GB:AZN Stock Forecast page.
AstraZeneca has received approval from the European Union for a fixed-duration regimen of its drug Calquence, in combination with venetoclax, with or without obinutuzumab, for the treatment of adult patients with previously untreated chronic lymphocytic leukaemia (CLL). This approval is based on positive results from the AMPLIFY Phase III trial, which demonstrated significant improvements in progression-free survival compared to standard chemoimmunotherapy. The approval provides a new all-oral treatment option that may help minimize long-term side effects and improve adherence, potentially impacting AstraZeneca’s market position in the oncology sector.
The most recent analyst rating on (GB:AZN) stock is a Buy with a £190.00 price target. To see the full list of analyst forecasts on AstraZeneca stock, see the GB:AZN Stock Forecast page.
AstraZeneca has announced that as of 31 May 2025, its issued share capital with voting rights consists of 1,550,657,962 ordinary shares. This figure is significant for shareholders as it serves as the denominator for calculating their interests under the UK Financial Conduct Authority’s Disclosure and Transparency Rules.
The most recent analyst rating on (GB:AZN) stock is a Buy with a £20000.00 price target. To see the full list of analyst forecasts on AstraZeneca stock, see the GB:AZN Stock Forecast page.
AstraZeneca’s Imfinzi has been recommended for approval by the CHMP in the EU as the first perioperative immunotherapy for muscle-invasive bladder cancer. The recommendation is based on the NIAGARA Phase III trial, which showed significant reductions in disease recurrence and death risk compared to neoadjuvant chemotherapy alone. This approval could transform treatment approaches in Europe, offering a new standard of care for patients with resectable muscle-invasive bladder cancer.
The most recent analyst rating on (GB:AZN) stock is a Buy with a £20000.00 price target. To see the full list of analyst forecasts on AstraZeneca stock, see the GB:AZN Stock Forecast page.
AstraZeneca’s Imfinzi has been recommended for approval in the EU as the first perioperative immunotherapy for muscle-invasive bladder cancer (MIBC), based on the NIAGARA Phase III trial results. The trial demonstrated significant reductions in the risk of disease progression and death, supporting Imfinzi’s potential to become a new standard of care in Europe, offering a much-needed treatment option for MIBC patients and potentially transforming the treatment landscape.
The most recent analyst rating on (GB:AZN) stock is a Buy with a £20000.00 price target. To see the full list of analyst forecasts on AstraZeneca stock, see the GB:AZN Stock Forecast page.
AstraZeneca announced the vesting of ordinary shares to CEO Pascal Soriot under the AstraZeneca Performance Share Plan. The award, granted in 2020, vested after a three-year performance period and a two-year holding period, resulting in 97% of the award vesting. This transaction reflects AstraZeneca’s commitment to rewarding its leadership based on performance, potentially impacting the company’s executive compensation strategy and stakeholder perceptions.
The most recent analyst rating on (GB:AZN) stock is a Buy with a £14500.00 price target. To see the full list of analyst forecasts on AstraZeneca stock, see the GB:AZN Stock Forecast page.
AstraZeneca has completed the acquisition of EsoBiotec, a biotechnology company known for its innovative in vivo cell therapies, particularly the Engineered NanoBody Lentiviral (ENaBL) platform. This acquisition, valued at up to $1 billion, positions AstraZeneca to enhance its cell therapy capabilities, potentially transforming cancer treatment by enabling quicker and more accessible therapies. The acquisition aligns with AstraZeneca’s strategic focus on oncology and immune-mediated diseases, aiming to redefine cancer care and address unmet needs in chronic diseases.
The most recent analyst rating on (GB:AZN) stock is a Buy with a £20000.00 price target. To see the full list of analyst forecasts on AstraZeneca stock, see the GB:AZN Stock Forecast page.